ARTMS

ARTMS Inc. operates at the forefront of medical isotope production, providing a critical alternative to traditional, reactor-based supply chains. The company was formally established in 2017, spun out from TRIUMF, Canada's particle accelerator center, following a government-funded project to develop solid target production of technetium-99m (Tc-99m). This initiative was a collaborative effort involving TRIUMF, BC Cancer, Lawson Health Research Institute, and the Center for Probe Development. The company's foundation was driven by the global Tc-99m shortage in 2009, which exposed the fragility of a supply chain reliant on a few aging nuclear reactors. In April 2024, ARTMS was acquired by Telix Pharmaceuticals, a move intended to vertically integrate Telix's supply chain and manufacturing capabilities. ARTMS will continue to operate as a standalone technology division within Telix.

ARTMS specializes in technology that allows for the decentralized production of high-demand medical isotopes using hospital-based cyclotrons. Its primary clients are hospitals, medical imaging centers, pharmaceutical distributors, and radiopharmaceutical companies that operate cyclotrons. The business model centers on selling its proprietary QUANTM Irradiation System (QIS™), related hardware, and single-use consumable targets. This empowers clients to produce isotopes on-site, providing them with control over their supply chain and mitigating risks associated with centralized production, such as shortages and high costs. By upgrading existing cyclotrons, ARTMS offers a cost-effective solution without the need for major new construction.

The company's flagship product is the QUANTM Irradiation System (QIS™), a comprehensive solution that enables the high-yield production of several crucial medical isotopes. The QIS™ consists of an automated pneumatic transfer system, a compact solid target station, and solutions for processing the solid targets. This system is compatible with most commonly installed cyclotrons and can be installed with minimal interruption to daily operations. A key benefit of the technology is its ability to produce large, cost-effective batches of isotopes like Technetium-99m (Tc-99m), Gallium-68 (Ga-68), Zirconium-89 (Zr-89), and Copper-64 (Cu-64). For instance, a single 90-minute run can produce over 100 patient doses of Ga-68 at a fraction of the traditional cost. The process also produces minimal long-lived radioactive waste, addressing significant environmental and disposal concerns associated with reactor-based methods. The technology has received approval from Health Canada for producing Tc-99m and has obtained a CE mark in Europe.

Keywords: medical isotopes, cyclotron production, radiopharmaceuticals, technetium-99m, gallium-68, zirconium-89, QUANTM Irradiation System, decentralized isotope production, nuclear medicine, medical imaging, particle accelerator technology, solid target technology, isotope supply chain, Telix Pharmaceuticals, TRIUMF spin-off, diagnostic imaging, oncology, cardiology, radiometals, isotope manufacturing